Novel Orally Active Hydrogen Sulfide-Releasing Compound, SG1002, Improves Left Ventricular Function and Survival in a Murine Model of Ischemic Cardiomyopathy
Hydrogen sulfide (H2S) is a gasotransmitter that has shown cardioprotective effects in the setting of myocardial injury such as acute myocardial infarction (MI) and pressure overload-induced heart failure. However, there are shortcomings in precision and control release from the use of traditional f...
Main Author: | Balan, Bharat |
---|---|
Format: | Others |
Published: |
VCU Scholars Compass
2017
|
Subjects: | |
Online Access: | http://scholarscompass.vcu.edu/etd/4937 http://scholarscompass.vcu.edu/cgi/viewcontent.cgi?article=6018&context=etd |
Similar Items
-
A Novel, Orally Active Hydrogen Sulfide-Releasing Compound, SG1002, Improves Left Ventricular Function with an Associated Induction of Angiogenesis in a Murine Model of Ischemia/Reperfusion
by: Evani, Om A
Published: (2018) -
A randomized clinical study assessing the effects of the antioxidants, resveratrol or SG1002, a hydrogen sulfide prodrug, on idiopathic oligoasthenozoospermia
by: Arturo Morales Martinez, et al.
Published: (2015-06-01) -
Long-term prognosis of left ventricular re-remodeling after surgery of ischemic cardiomyopathy: the potential of tomographic radionuclide ventriculography
by: V. V. Shipulin, et al.
Published: (2020-12-01) -
Discrepancy between MRI and echocardiography in assessing functional left ventricular parameters and scar characteristics in patients with chronic ischemic cardiomyopathy
by: Sherif Gouda, et al.
Published: (2015-09-01) -
Criteria of eligibility of patients with ischemic cardiomyopathy for revascularization and other surgical procedures
by: N.D. Oryshchyn
Published: (2016-09-01)